Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.
| Revenue (Most Recent Fiscal Year) | $129.42M |
| Net Income (Most Recent Fiscal Year) | $17.38M |
| PE Ratio (Current Year Earnings Estimate) | 15.88 |
| PE Ratio (Trailing 12 Months) | 18.10 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.33 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 16.96 |
| Pre-Tax Margin (Trailing 12 Months) | 15.10% |
| Net Margin (Trailing 12 Months) | 14.29% |
| Return on Equity (Trailing 12 Months) | 22.68% |
| Return on Assets (Trailing 12 Months) | 16.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.61 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $0.18 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 79.64M |
| Free Float | 71.68M |
| Market Capitalization | $273.98M |
| Average Volume (Last 20 Days) | 1.11M |
| Beta (Past 60 Months) | 2.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.41% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |